A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.

Martin St John Sutton, Marc Rendell, Paresh Dandona, J. F. Dole, Karen Murphy, Rita Patwardhan, Jai Patel, Martin Freed

Research output: Contribution to journalArticle

239 Citations (Scopus)

Abstract

OBJECTIVE: This open-label, active-controlled study investigated the cardiac safety and antihyperglycemic effect of rosiglitazone (RSG) in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Of the 203 patients randomly assigned to RSG (4 mg b.i.d.) or glyburide (GLB) (titrated to achieve optimal glycemic control for the first 8 weeks only to limit the risk of hypoglycemia; mean 10.5 mg/day), 118 had an echocardiogram performed at week 52. Left ventricular (LV) mass index, ejection fraction, and left ventricular end-diastolic volume were assessed by M-mode echocardiography at baseline and weeks 12, 28, and 52; 24-h ambulatory blood pressure was assessed at baseline and at weeks 28 and 52. Glycemic control was assessed by measuring fasting plasma glucose (FPG) and HbA(1c). RESULTS: Neither treatment produced an increase in LV mass index that exceeded 1 SD. Ejection fraction did not change in either group. Both groups had clinically insignificant increases in LV end-diastolic volume. RSG, but not GLB, caused a statistically significant reduction in ambulatory diastolic blood pressure. Both treatments reduced HbA(1c) and FPG. CONCLUSIONS: A total of 52 weeks of therapy with RSG (4 mg b.i.d.) did not adversely affect cardiac structure or function in patients with type 2 diabetes and produced significant and sustained reductions in hyperglycemia. Decreases in ambulatory diastolic blood pressure with RSG were superior to those with GLB.

Original languageEnglish
Pages (from-to)2058-2064
Number of pages7
JournalDiabetes Care
Volume25
Issue number11
StatePublished - Nov 2002
Externally publishedYes

Fingerprint

rosiglitazone
Glyburide
Type 2 Diabetes Mellitus
Blood Pressure
Stroke Volume
Fasting
Glucose
Hypoglycemia
Hypoglycemic Agents
Hyperglycemia
Echocardiography
Research Design
Therapeutics
Safety

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

St John Sutton, M., Rendell, M., Dandona, P., Dole, J. F., Murphy, K., Patwardhan, R., ... Freed, M. (2002). A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care, 25(11), 2058-2064.

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. / St John Sutton, Martin; Rendell, Marc; Dandona, Paresh; Dole, J. F.; Murphy, Karen; Patwardhan, Rita; Patel, Jai; Freed, Martin.

In: Diabetes Care, Vol. 25, No. 11, 11.2002, p. 2058-2064.

Research output: Contribution to journalArticle

St John Sutton, M, Rendell, M, Dandona, P, Dole, JF, Murphy, K, Patwardhan, R, Patel, J & Freed, M 2002, 'A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.', Diabetes Care, vol. 25, no. 11, pp. 2058-2064.
St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002 Nov;25(11):2058-2064.
St John Sutton, Martin ; Rendell, Marc ; Dandona, Paresh ; Dole, J. F. ; Murphy, Karen ; Patwardhan, Rita ; Patel, Jai ; Freed, Martin. / A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. In: Diabetes Care. 2002 ; Vol. 25, No. 11. pp. 2058-2064.
@article{d3670dedb5d146f4b9c9a742d7858f13,
title = "A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.",
abstract = "OBJECTIVE: This open-label, active-controlled study investigated the cardiac safety and antihyperglycemic effect of rosiglitazone (RSG) in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Of the 203 patients randomly assigned to RSG (4 mg b.i.d.) or glyburide (GLB) (titrated to achieve optimal glycemic control for the first 8 weeks only to limit the risk of hypoglycemia; mean 10.5 mg/day), 118 had an echocardiogram performed at week 52. Left ventricular (LV) mass index, ejection fraction, and left ventricular end-diastolic volume were assessed by M-mode echocardiography at baseline and weeks 12, 28, and 52; 24-h ambulatory blood pressure was assessed at baseline and at weeks 28 and 52. Glycemic control was assessed by measuring fasting plasma glucose (FPG) and HbA(1c). RESULTS: Neither treatment produced an increase in LV mass index that exceeded 1 SD. Ejection fraction did not change in either group. Both groups had clinically insignificant increases in LV end-diastolic volume. RSG, but not GLB, caused a statistically significant reduction in ambulatory diastolic blood pressure. Both treatments reduced HbA(1c) and FPG. CONCLUSIONS: A total of 52 weeks of therapy with RSG (4 mg b.i.d.) did not adversely affect cardiac structure or function in patients with type 2 diabetes and produced significant and sustained reductions in hyperglycemia. Decreases in ambulatory diastolic blood pressure with RSG were superior to those with GLB.",
author = "{St John Sutton}, Martin and Marc Rendell and Paresh Dandona and Dole, {J. F.} and Karen Murphy and Rita Patwardhan and Jai Patel and Martin Freed",
year = "2002",
month = "11",
language = "English",
volume = "25",
pages = "2058--2064",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.

AU - St John Sutton, Martin

AU - Rendell, Marc

AU - Dandona, Paresh

AU - Dole, J. F.

AU - Murphy, Karen

AU - Patwardhan, Rita

AU - Patel, Jai

AU - Freed, Martin

PY - 2002/11

Y1 - 2002/11

N2 - OBJECTIVE: This open-label, active-controlled study investigated the cardiac safety and antihyperglycemic effect of rosiglitazone (RSG) in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Of the 203 patients randomly assigned to RSG (4 mg b.i.d.) or glyburide (GLB) (titrated to achieve optimal glycemic control for the first 8 weeks only to limit the risk of hypoglycemia; mean 10.5 mg/day), 118 had an echocardiogram performed at week 52. Left ventricular (LV) mass index, ejection fraction, and left ventricular end-diastolic volume were assessed by M-mode echocardiography at baseline and weeks 12, 28, and 52; 24-h ambulatory blood pressure was assessed at baseline and at weeks 28 and 52. Glycemic control was assessed by measuring fasting plasma glucose (FPG) and HbA(1c). RESULTS: Neither treatment produced an increase in LV mass index that exceeded 1 SD. Ejection fraction did not change in either group. Both groups had clinically insignificant increases in LV end-diastolic volume. RSG, but not GLB, caused a statistically significant reduction in ambulatory diastolic blood pressure. Both treatments reduced HbA(1c) and FPG. CONCLUSIONS: A total of 52 weeks of therapy with RSG (4 mg b.i.d.) did not adversely affect cardiac structure or function in patients with type 2 diabetes and produced significant and sustained reductions in hyperglycemia. Decreases in ambulatory diastolic blood pressure with RSG were superior to those with GLB.

AB - OBJECTIVE: This open-label, active-controlled study investigated the cardiac safety and antihyperglycemic effect of rosiglitazone (RSG) in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Of the 203 patients randomly assigned to RSG (4 mg b.i.d.) or glyburide (GLB) (titrated to achieve optimal glycemic control for the first 8 weeks only to limit the risk of hypoglycemia; mean 10.5 mg/day), 118 had an echocardiogram performed at week 52. Left ventricular (LV) mass index, ejection fraction, and left ventricular end-diastolic volume were assessed by M-mode echocardiography at baseline and weeks 12, 28, and 52; 24-h ambulatory blood pressure was assessed at baseline and at weeks 28 and 52. Glycemic control was assessed by measuring fasting plasma glucose (FPG) and HbA(1c). RESULTS: Neither treatment produced an increase in LV mass index that exceeded 1 SD. Ejection fraction did not change in either group. Both groups had clinically insignificant increases in LV end-diastolic volume. RSG, but not GLB, caused a statistically significant reduction in ambulatory diastolic blood pressure. Both treatments reduced HbA(1c) and FPG. CONCLUSIONS: A total of 52 weeks of therapy with RSG (4 mg b.i.d.) did not adversely affect cardiac structure or function in patients with type 2 diabetes and produced significant and sustained reductions in hyperglycemia. Decreases in ambulatory diastolic blood pressure with RSG were superior to those with GLB.

UR - http://www.scopus.com/inward/record.url?scp=0036833805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036833805&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 2058

EP - 2064

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 11

ER -